40 IU HGH + water – Pooyesh Darou Biopharmaceuticals – PHARMA GRADE IRAN -Exp.Dec 29/23

Please read about expire dates

https://www.propublica.org/article/the-myth-of-drug-expiration-dates

10 single kits 4 iu each with glass amp 1 ml of water.

10 kits x 4iu each

Somatropin or the growth hormone (GH) is one of the most abundant hormones produced by the anterior pituitary lobe. It is synthesized and secreted by specific cells, the somatotropes. GH daily secretion varies through life. Its concentration is high in children, reaching maximum levels in adolescence, while in adulthood, the concentration decreases progressively. GH secretion occurs in pulsatile and irregular way; between pulses, the flowing GH decreases up to levels that are sometimes non-detectable through some of the current methodologies. Secretion pulse amplitude achieves maximum levels at night and the most constant GH secretion occurs little after deep sleep onset.

PDgrowth^® contains somatropin, the recombinant human growth hormone, whose amino acid sequence is identical to the natural growth hormone. PDgrowth^® active ingredient is made up of a unique 191 amino acid polypeptide chain. Its molecular weight is 22,124 Da. It contains two disulphide bonds and it is not glycosylated. It is produces by recombinant DNA technology.

The following recommendations are based on the applied dose in controlled clinical trials that demonstrated the efficacy of the treatment.

– GH deficiency in pediatric patients: by sub-cutaneous or intramuscular injection, 0.069–0.117 IU/kg daily or 0.7–1 mg/m² daily.

– Turner syndrome in pediatric patients: by subcutaneous injection, 0.135–0.15 IU/kg daily or 1.4 mg/m² daily.

– Prader-Willi syndrome in pediatric patients: by subcutaneous injection in children with growth velocity greater than 1 cm/year, in combination with energy-restricted diet, 0.105 IU/kg daily or 1 mg/m² daily; max. 2.7 mg daily.

– Small pediatric patients regarding their gestational age: by subcutaneous injection, 0.105 IU/kg daily or 1 mg/m² daily.

– Growth hormone deficiency in adult patients: by subcutaneous injection, initially 0.45–0.9 IU daily gradually increased if required to max. 3 IU daily; use minimum effective dose (requirements may decrease with age).

– Chronic renal insufficiency in pediatric patients: by subcutaneous injection, 0.135–0.15 IU/kg daily or 1.4 mg/m² daily (higher doses may be needed) adjusted if necessary after 6 months.

– Wasting syndrome in AIDS patients: 0.26-0.3 IU/Kg per day or 0.3 IU/kg given as a daily subcutaneous injection.

– Idiopathic short stature: by subcutaneous injection 1.11-1.41 IU/kg divided into equal doses 6-7 days per week.